NEW YORK (GenomeWeb) – Quanterix today announced a strategic investment in ImmunArray, a move that could strengthen each company's efforts in addressing neurodegenerative disease diagnostics.

Under the terms of the agreement, Lexington, Massachusetts-based Quanterix will gain access to ImmunArray's biomarker portfolio for traumatic brain injury and add select biomarkers to its multiplex panel for neurology research. ImmunArray, based in both Israel and Virginia, will in turn gain access to Quantertix's Simoa single-molecule array technology.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.

Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.